GRAL Stock Risk & Deep Value Analysis
Grail Inc
Healthcare • Diagnostics & Research
DVR Score
out of 10
The Bottom Line on GRAL
We analyzed Grail Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran GRAL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈GRAL Performance Overview3yr weekly
Unlock GRAL Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
GRAL Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Low
About Grail Inc (GRAL)
Sector
Healthcare
Industry
Diagnostics & Research
Market Cap Category
mid
Market Cap
$3.57B
GRAL Deep Value Analysis
Compare GRAL to Similar Stocks
See how Grail Inc stacks up against related companies in our head-to-head analysis.
GRAL Red Flags & Warning Signs
Premium- ⚠
FDA regulatory delays or outright rejection of PMA application
- ⚠
Intensified competitive entry with comparable or superior MCED tests
- ⚠
Negative results from ongoing or future clinical trials
- ⚠
Need for significant equity financing leading to dilution
Unlock GRAL Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
GRAL Financial Health Metrics
Market Cap
$3.57B
GRAL Competitive Moat Analysis
PremiumMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Grail's moat is durable due to the immense scientific and regulatory barriers to entry in multi-cancer early detection, requiring vast clinical trials, proprietary algorithms, and significant capital. Its first-mover status in data accumulation further strengthens this.
GRAL Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
GRAL Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late April/early May 2026)
- •Updates on FDA PMA application progress for Galleri
- •Expansion of commercial partnerships for Galleri distribution and adoption
Medium-Term (6-18 months)
- •FDA PMA approval for the Galleri multi-cancer early detection test (primary catalyst)
- •Significant expansion of private and public payor reimbursement coverage for Galleri
- •Initiation of new clinical trials for broader indications or expanded use cases
Long-Term (18+ months)
- •Establishment of dominant market share in the multi-cancer early detection market
- •Successful international expansion of Galleri and pipeline products
- •Development and commercialization of next-generation diagnostic platforms
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
GRAL Bull Case: What Could Go Right
- ✓
FDA PMA approval official announcement and timeline for commercial launch
- ✓
Acceleration in Galleri test adoption rates and reimbursement coverage expansion
- ✓
Improvements in cash burn trajectory and progress towards profitability
- ✓
New strategic partnerships with major healthcare systems or payors
Bull Case Analysis
See what could go right with Premium
Never miss a move on GRAL
Create a free account to set price alerts and get notified on Telegram when GRAL hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Grail Inc (GRAL)?
As of February 16, 2026, Grail Inc has a DVR Score of 7.9 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Grail Inc?
Grail Inc's market capitalization is approximately $3.6B. The company operates in the Healthcare sector within the Diagnostics & Research industry.
What ticker symbol does Grail Inc use?
GRAL is the ticker symbol for Grail Inc. The company trades on the NMS.
What is the risk level for GRAL stock?
Our analysis rates Grail Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the GRAL DVR analysis updated?
Our AI-powered analysis of Grail Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on February 16, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.